Novartis AG’s animal-health business is drawing interest from drugmakers including Eli Lilly & Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of the matter said.
Eli Lilly & Co., the biggest U.S. maker of insulin products, will pour another $700 million into manufacturing capacity, more than tripling its investment in the expanding market for diabetes treatments.
A new class of cholesterol-lowering medicines from Pfizer Inc. and Amgen Inc. may struggle to meet sales projections, as latest treatment guidelines suggest doctors should prescribe only drugs proven to help the heart.
U.S. regulators won’t require Amgen Inc., Sanofi, Pfizer Inc. and other companies developing the next class of cardiovascular medicines to prove the therapies prevent heart attacks and death before they’re approved.
U.S. lawmakers, influenced by companies including Cisco Systems Inc., Eli Lilly & Co. and Qualcomm Inc., are considering the second set of patent-law changes in three years as the courts try to race ahead of Congress.